Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
DKS Dick's Sporting Goods Inc
PETZ TDH Holdings Inc
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
$145.24
Day's Change
0.16 (0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
147.47
Day's Low
144.35
Volume
(Light)
Volume:
4,154,372

10-day average volume:
6,234,677
4,154,372

UPDATE: Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment

7:46 am ET September 16, 2020 (MarketWatch)
Print

Shares of Eli Lilly & Co. (LLY) gained 2.6% in premarket trading on Wednesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalization as well as viral load in some COVID-19 patients. The investigational therapy, LY-CoV555, is produced using neutralizing antibodies gathered from patients who have recovered from COVID-19. The ongoing, randomized, double-blind, placebo-controlled Phase 2 study is expected to enroll a total of 800 participants, all of whom have mild to moderate symptoms and are being treated with LY-CoV555 in an outpatient setting. Lilly said the rate of hospitalization and emergency room visit was 1.7% for patients taking the drug, while the rate of hospitalization and ER visits for patients taking the placebo was 6.0%. "The results reinforce our conviction that neutralizing antibodies can help in the fight against COVID-19," Dr. Daniel Skovronsky, Lilly's chief scientific officer, said in a news release. The full data is expected to be published in a peer-reviewed journal. Lilly's stock is up 14.2% so far this year, while the S&P 500 has rallied 5.2%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 16, 2020 07:46 ET (11:46 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.